Literature DB >> 2267310

Antimuscarinic drugs in the treatment of movement disorders.

S Fahn1, R Burke, Y Stern.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2267310     DOI： 10.1016/s0079-6123(08)60922-x

Source DB:  PubMed          Journal:  Prog Brain Res        ISSN： 0079-6123            Impact factor:   2.453


× No keyword cloud information.
  7 in total

1.  Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice.

Authors:  Weilie Zhang; Anthony S Basile; Jesus Gomeza; Laura A Volpicelli; Allan I Levey; Jürgen Wess
Journal:  J Neurosci       Date:  2002-03-01       Impact factor: 6.167

2.  Hyperactivity and intact hippocampus-dependent learning in mice lacking the M1 muscarinic acetylcholine receptor.

Authors:  T Miyakawa; M Yamada; A Duttaroy; J Wess
Journal:  J Neurosci       Date:  2001-07-15       Impact factor: 6.167

3.  Muscarinic Acetylcholine Receptor Subtypes as Potential Drug Targets for the Treatment of Schizophrenia, Drug Abuse and Parkinson's Disease.

Authors:  Ditte Dencker; Morgane Thomsen; Gitta Wörtwein; Pia Weikop; Yinghong Cui; Jongrye Jeon; Jürgen Wess; Anders Fink-Jensen
Journal:  ACS Chem Neurosci       Date:  2012       Impact factor: 4.418

Review 4.  Nonmotor manifestations of dystonia: a systematic review.

Authors:  Daniel J Kuyper; Veronica Parra; Shanae Aerts; Michael S Okun; Benzi M Kluger
Journal:  Mov Disord       Date:  2011-04-11       Impact factor: 10.338

5.  Muscarinic receptor binding changes in postmortem Parkinson's disease.

Authors:  Caitlin McOmish; Geoff Pavey; Catriona McLean; Malcolm Horne; Brian Dean; Elizabeth Scarr
Journal:  J Neural Transm (Vienna)       Date:  2016-11-21       Impact factor: 3.575

6.  Cholinergic connectivity: it's implications for psychiatric disorders.

Authors:  Elizabeth Scarr; Andrew S Gibbons; Jaclyn Neo; Madhara Udawela; Brian Dean
Journal:  Front Cell Neurosci       Date:  2013-05-03       Impact factor: 5.505

7.  Discovery of the First Selective M4 Muscarinic Acetylcholine Receptor Antagonists with in Vivo Antiparkinsonian and Antidystonic Efficacy.

Authors:  Mark S Moehle; Aaron M Bender; Jonathan W Dickerson; Daniel J Foster; Aidong Qi; Hyekyung P Cho; Yuping Donsante; Weimin Peng; Zoey Bryant; Kaylee J Stillwell; Thomas M Bridges; Sichen Chang; Katherine J Watson; Jordan C O'Neill; Julie L Engers; Li Peng; Alice L Rodriguez; Colleen M Niswender; Craig W Lindsley; Ellen J Hess; P Jeffrey Conn; Jerri M Rook
Journal:  ACS Pharmacol Transl Sci       Date:  2021-08-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.